Eli Lilly and Company has announced that the FDA has approved Strattera for maintenance treatment of attention-deficit hyperactivity disorder in children and adolescents.
Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the...